Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm
COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Life (Basel, Switzerland) - 12(2022), 4 vom: 25. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rabiu Abubakar, Abdullahi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/life12040478 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339841427 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339841427 | ||
| 003 | DE-627 | ||
| 005 | 20231226003809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/life12040478 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339841427 | ||
| 035 | |a (NLM)35454970 | ||
| 035 | |a (PII)478 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rabiu Abubakar, Abdullahi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a COVID-19-infected patients require an intact immune system to suppress viral replication and prevent complications. However, the complications of SARS-CoV-2 infection that led to death were linked to the overproduction of proinflammatory cytokines known as cytokine storm syndrome. This article reported the various checkpoints targeted to manage the SARS-CoV-2-induced cytokine storm. The literature search was carried out using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Journal articles that discussed SARS-CoV-2 infection and cytokine storm were retrieved and appraised. Specific checkpoints identified in managing SARS-CoV-2 induced cytokine storm include a decrease in the level of Nod-Like Receptor 3 (NLRP3) inflammasome where drugs such as quercetin and anakinra were effective. Janus kinase-2 and signal transducer and activator of transcription-1 (JAK2/STAT1) signaling pathways were blocked by medicines such as tocilizumab, baricitinib, and quercetin. In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Blockade of IL-1 with drugs such as canakinumab and anakinra, and inhibition of Bruton tyrosine kinase (BTK) with zanubrutinib and ibrutinib was also beneficial. These agents' overall mechanisms of action involve a decrease in circulating proinflammatory chemokines and cytokines and or blockade of their receptors. Consequently, the actions of these drugs significantly improve respiration and raise lymphocyte count and PaO2/FiO2 ratio. Targeting cytokine storms' pathogenesis genetic and molecular apparatus will substantially enhance lung function and reduce mortality due to the COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a hyperinflammation | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a interleukins | |
| 650 | 4 | |a pathogenesis | |
| 700 | 1 | |a Ahmad, Rahnuma |e verfasserin |4 aut | |
| 700 | 1 | |a Rowaiye, Adekunle Babajide |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Sayeeda |e verfasserin |4 aut | |
| 700 | 1 | |a Iskandar, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Dutta, Siddhartha |e verfasserin |4 aut | |
| 700 | 1 | |a Oli, Angus Nnamdi |e verfasserin |4 aut | |
| 700 | 1 | |a Dhingra, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Tor, Maryam Abba |e verfasserin |4 aut | |
| 700 | 1 | |a Etando, Ayukafangha |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Santosh |e verfasserin |4 aut | |
| 700 | 1 | |a Irfan, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Gowere, Marshall |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Kona |e verfasserin |4 aut | |
| 700 | 1 | |a Akter, Farhana |e verfasserin |4 aut | |
| 700 | 1 | |a Jahan, Dilshad |e verfasserin |4 aut | |
| 700 | 1 | |a Schellack, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Haque, Mainul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life (Basel, Switzerland) |d 2011 |g 12(2022), 4 vom: 25. März |w (DE-627)NLM243284799 |x 2075-1729 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:4 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/life12040478 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 4 |b 25 |c 03 | ||